UroGen Pharma URGN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -94.8%+55.9pp | -139.8%+0.5pp | -170.6%-41.5pp | -164.4%-30.8pp | -150.7%-26.9pp | |
| Free cash flow margin | -118.2%-1.3pp | -148.2%-40.9pp | -143.1%-35.3pp | -131.1%-29.9pp | -116.9%-19.1pp | |
| Returns | ||||||
| Return on assets | -53.2%+8.6pp | -63.1%-8.5pp | -67.6%-21.1pp | -63.2%-3.0pp | -61.8%+4.8pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.2× | 0.5×+0.1× | 0.4×0.0× | 0.4×-0.1× | 0.4×-0.1× | |
| Liquidity | ||||||
| Current ratio | 4.7×-1.0× | 4×-2.0× | 4×-5.0× | 4.1×-4.0× | 5.6×-1.8× | |
| Quick ratio | 4.3×-1.2× | 3.7×-2.2× | 3.8×-5.0× | 4×-3.9× | 5.5×-1.7× | |
| Cash ratio | 2.2×-0.3× | 2.4×-1.4× | 2.1×-1.7× | 2×-4.5× | 2.5×-2.5× | |
| Leverage | ||||||
| Debt-to-assets | 0.8×+0.3× | 0.6×+0.2× | 0.7×+0.3× | 0.6×+0.3× | 0.5×0.0× | |
| Valuation | ||||||
| Market capitalization | $875.31M+71.7% | $1.1B+144% | $922.97M+76.5% | $635.82M+4.9% | $509.8M-5.9% | |
| Enterprise value | $962.43M+80.9% | $1.12B+177% | $962.87M+84.9% | $670.39M+38.1% | $532.13M+4.4% | |
| Price / sales | 6.2×+0.7× | 10×+5.0× | 9.6×+3.7× | 6.7×-0.4× | 5.5×-0.9× | |
| EV / sales | 6.9×+1.1× | 10.2×+5.7× | 10×+4.1× | 7.1×+1.4× | 5.8×-0.3× | |
| Free cash flow yield | -19%+2.1pp | -14.8%+6.8pp | -15%+3.5pp | -19.4%-5.2pp | -21.1%-5.8pp | |
| Earnings yield | -15.2%+11.9pp | -14%+14.2pp | -17.8%+4.2pp | -24.4%-5.6pp | -27.2%-7.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- UroGen Pharma (URGN) runs a 89.7% gross margin and a -329.7% operating margin, with a -94.8% net margin.
- Where do UroGen Pharma's ratios come from?
- Every ratio is computed from UroGen Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.